1. Wang Z, Zhang G, Wu J, Jia M. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect. Drug Discov Ther. 2013; 7(4): 137-143.
2. Özer B, Serin E, Yılmaz U, Gümürdülü Y, Saygılı OB, Kayaselçuk F, Boyacioğlu S. Clinicopathologic features and risk factors for hepatocellular carcinoma: Results from a single center in southern Turkey. Turk J Gastroenterol. 2003; 14(2): 85-90.
3. Uyanıkoğlu A, Coşkun M, Albayrak F, Öztürk Y, Tay A, Kibar Yİ. Genç yaşta hepatsellüler Karsinoma İle Prezente Olan, Hepatit B’ye Bağlı İki Karaciğer Sirozu Vakası [Two Cases with Liver Cirrhosis Secondary to Hepatitis B that Prezented with Hepatocellular at Young Age]. Dicle Tıp Dergisi. 2013; 40(1): 131-133.
4. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW. Influence of hepatitis delta virus infection on morbidity and mortality in compensatedcirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000; 46(3): 420-426.
5. Uyanıkoğlu A, Coşkun M, Albayrak F, Aktaş F, Binici DN, Öztürk Y. Erzurum İli ve Çevresinde Kan Donörlerinde Hepatit B Seroprevalansı [Seroprevalance of Hepatitis B Among Healty Blood Donors in Erzurum region]. Viral Hepatit Dergisi [Viral Hepatitis Journal] 2012;18(3):91-93.
6. Uyanıkoğlu A, Aydoğan T, Nar H, Çetin B, Sert U. Şanlıurfa Yöresinde HBsAg (+) Hastaların Klinik Dağılımı ve Demografik Özellikleri. IX. Ulusal Hepatoloji Kongresi Bildiri Özetleri Kitabı. 28 Mayıs- 1 Haziran 2013, İstanbul, P-059, 141.
7. Albayrak A, Coşkun M, Uyanıkoğlu A, Bayır Y, Yılmaz H, Kibar Yİ, Tay A, Albayrak F. Kronik Hepatit Delta’sı Olan Hastaların Pegile İnterferon Tedavi Yanıtlarının Değerlendirilmesi. Vir Hep Derg. 2012; 18(2): 68-70.
8. Ettorre GM, Laurenzi A, Vennarecci G. Downstaging Hepatocellular Carcinoma with Yttrium-90 radioembolization: Resection or transplantation? Eur J Surg Oncol. 2014; 40(6): 789-790.
9. Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, Gaba RC, Mulcahy MF, Baker T, Sato K, Hickey R, Ganger D, Riaz A, Fryer J, Caicedo JC, Abecassis M, Kulik L, Salem R. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013; 59(5): 1029-1036.
10. Memon K, Lewandowski RJ, Riaz A, Salem R. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. Recent Results Cancer Res. 2013; 190: 207-224.
11. Romeo R, Foglieni B, Casazza G, Spreafico M, Colombo M, Prati D. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS One. 2014; 9(3): 92062.
12. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009; 136(5): 1629-1638.
13. Kim do Y, Han KH. How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. Dig Dis. 2012; 30(6): 598-602.
14. Felga G, Evangelista AS, Salvalaggio PR, Curvelo LA, Della Guardia B, Almeida MD, Afonso RC, Ferraz-Neto BH. Clinical profile and liver explant findings in patients with and without pretransplant downstaging for hepatocellular caravcinoma. Transplant Proc. 2012; 44(8): 2399-2402.
15. Peynircioğlu B, Çil B, Bozkurt F, Aydemir E, Uğur Ö, Balkancı F. Rezeke edilemeyen karaciğer kanserinin tedavisi için radyoembolizasyon: tek bir merkezdeki ilk deneyimler. [Radioembolization for the treatment of unresectable liver cancer: initial experience at a single center]. Diagn Interv Radiol. 2010; 16: 70-78.
16. Inarrairaegui M, Pardo F, Bilbao JI, Rotellar F, Benito A, D’Avola D, Herrero JI, Rodriguez M, Martí P, Zozaya G, Dominguez I, Quiroga J, Sangro B. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol. 2012; 38(7): 594-601.
17. Yu CY, Ou HY, Huang TL, Chen TY, Tsang LL, Chen CL, Cheng YF. Hepatocellular carcinoma downstaging in liver transplantation. Transplant Proc. 2012; 44(2): 412-414.
18. Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, Leung T, Han KH, Poon RT. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013; 84(5): 311-318.
19. Kim YH, Kim do Y. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know. Oncology. 2013; 84(Suppl 1): 34-39.
20. Takayasu K. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective. Oncology. 2013; 84(Suppl 1): 28-33.
21. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013; 57(5): 1826-1837.